1. Introduction {#sec1-cancers-11-00887}
===============

Multiple myeloma (MM) is a neoplasm of terminally differentiated plasma cells (PC), which at diagnosis is usually present throughout the bone marrow (BM) and frequently, with disease progression, spreads to extramedullary locations. The treatment of MM has witnessed significant progress with the introduction of proteasome inhibitors and immunomodulatory agents; however, the disease remains incurable with MM cells acquiring resistance to systemic therapies due to the accumulation of additional mutations that are often not present during the initial stages of the disease \[[@B1-cancers-11-00887]\]. Resistance to therapy is mediated through the genetic evolution of MM cells under selective pressure treatment with more resistant clones emerging that possess growth and survival advantages \[[@B2-cancers-11-00887]\].

Next-generation deep sequencing of MM tumor specimens has identified widespread genetic heterogeneity in MM \[[@B3-cancers-11-00887],[@B4-cancers-11-00887]\]. Gene expression profiling (GEP) studies of PC isolated from patients presenting with the pre-MM precursor syndrome, monoclonal gammopathy of undetermined significance (MGUS), and symptomatic MM, have identified specific transcriptional changes that occur at different stages of the disease and these studies have reported pathways that had not been previously implicated in MM pathogenesis \[[@B5-cancers-11-00887]\]. The current practice for obtaining genetic information about the tumor is to perform sequential BM biopsies and this is confounded by the known inter and intra-clonal spatial and genetic heterogeneity of the tumor(s) \[[@B1-cancers-11-00887],[@B2-cancers-11-00887],[@B6-cancers-11-00887]\]. An alternative approach that we believe will provide a more comprehensive transcriptional picture is to analyze the extracellular RNA (exRNA) from the peripheral blood (PB) plasma, as this theoretically contains genetic material that arises not only from multiple independent MM tumors but also from the tumor microenvironment (TME).

Nucleic acids are released into the plasma and serum through cellular apoptosis, necrosis, and the spontaneous release of DNA/RNA-lipoprotein complexes, amongst other sources \[[@B7-cancers-11-00887]\]. The presence of cell-free (cf) nucleic acids in the human blood was described more than 60 years ago \[[@B8-cancers-11-00887]\]. A number of recent studies in breast, ovarian, lung, and colorectal cancers have indicated that tumor(s) from both primary and secondary sites release nucleic acids into the PB, as such, circulating cfDNA contains a representation of the entire genome of the tumor with DNA sourced from multiple independent tumors. Whole genome sequencing and whole exome sequencing of the cfDNA can be utilized to identify mutations associated with acquired resistance to cancer therapy without the need to perform sequential biopsies of the tumor \[[@B9-cancers-11-00887],[@B10-cancers-11-00887]\]. Also, some studies have uncovered the presence of microRNAs and specific long noncoding RNAs in the exosomes, an extracellular vesicle subtype ranging from 30--150 nm in size \[[@B11-cancers-11-00887]\], isolated from the blood of MM patients \[[@B12-cancers-11-00887],[@B13-cancers-11-00887]\]. However, exRNA has not been systematically explored, with only a limited number of studies exploring the relevance of specific mRNA transcripts \[[@B14-cancers-11-00887],[@B15-cancers-11-00887],[@B16-cancers-11-00887],[@B17-cancers-11-00887],[@B18-cancers-11-00887]\]. More recently, technologies have advanced that promote the reliable extraction and analysis of exRNA using high-throughput sequencing technologies, and a limited number of studies have also performed whole transcriptome studies of exRNA in pregnancy and Alzheimer's disease \[[@B19-cancers-11-00887],[@B20-cancers-11-00887],[@B21-cancers-11-00887]\]. However, to our knowledge, no studies have explored the whole transcriptome of exRNA in MM or other cancers.

Global gene expression profiling of PC from normal, MGUS, smoldering (asymptomatic) myeloma (SMM), and symptomatic MM patients has indicated that MGUS patients have a profile that is different to SMM and MM patients and that a gene-based classification system can be employed for MM \[[@B22-cancers-11-00887],[@B23-cancers-11-00887],[@B24-cancers-11-00887]\]. In this study, we profiled the whole transcriptome of exRNA obtained from the PB plasma of healthy controls (HC) and MM patients to identify potential biomarkers for both newly diagnosed (NDMM) and relapsed and refractory (RRMM) MM patients.

2. Materials and Methods {#sec2-cancers-11-00887}
========================

2.1. Peripheral Blood (PB) Collection and Processing {#sec2dot1-cancers-11-00887}
----------------------------------------------------

Peripheral blood (PB) samples were obtained from healthy volunteers (HC) and MM patients using 10 mL Streck RNA blood collection tubes (BCTs) following informed consent as per the Alfred Hospital Human Research and Ethics Committee. Immediately upon sample collection, the tubes were inverted to mix the blood with the preservative in the collection tube. The patented preservative in Cell-Free RNA BCT preserves exRNA in plasma and prevents the release of non-target background RNA from blood cells during sample processing and storage \[[@B25-cancers-11-00887],[@B26-cancers-11-00887]\]. The Streck RNA tubes allow the collection of high-quality stabilized exRNA for rare target detection and determining accurate exRNA concentrations. Streck RNA BCT tubes were stored at room temperature and processed for plasma collection within 24 h of PB collection. Plasma was separated from PB through centrifugation at 820× *g* for 10 min. The supernatant was collected without disturbing the cellular layer and centrifuged again at 16,000× *g* for 10 min to remove any residual cellular debris. The supernatant was collected and stored at −80 °C until exRNA extraction.

2.2. exRNA Extraction {#sec2dot2-cancers-11-00887}
---------------------

Frozen plasma samples (6 mL) were used to extract the exRNA using the QIAamp circulating nucleic acid kit (Qiagen, Hilden, Germany), according to the manufacturers' instructions. Subsequently, a Qubit 2.0 Fluorometer (Life Technologies, Victoria, Australia) was used to measure the RNA yield, according to the manufacturer's instructions with freshly prepared RNA standards. The maximum input volume utilized for the QUBIT assay was 5 μL. The RNA concentration was quantified as being between 0.5--90 ng/μL. The extracted RNA was stored at −80 °C until further processing for RNA-Seq.

2.3. Transcriptome Library Construction and Sequencing {#sec2dot3-cancers-11-00887}
------------------------------------------------------

After the RNA sample was treated using the Ribo-Zero Gold rRNA Removal Kit (Illumina, San Diego, CA, USA), a total amount of 100 ng RNA was used for cDNA library construction using the TruSeq™ RNA Library Preparation Kit v2 protocol (Illumina, San Diego, CA, USA), as previously described \[[@B27-cancers-11-00887]\]. Then, the amplified cDNA libraries were assessed for quality using both the Agilent 2100 Bioanalyzer and qRT-PCR. After primer ligation sequencing, qRT-PCR was again used for quantification, and the final library was sequenced on an Illumina HiSeq 2000 platform (paired-end 100 bp) at the Australian Genomics Research Facility (Melbourne, Australia).

2.4. Analysis of Transcriptome Data {#sec2dot4-cancers-11-00887}
-----------------------------------

Raw transcriptome sequencing data were cleaned using SOAPnuke under default parameters \[[@B28-cancers-11-00887]\]. The clean reads were aligned to the human reference genome (ENSEMBL, GRCH38.85) using Hisat2 and the expression of protein-coding and noncoding genes were profiled using Stringtie \[[@B29-cancers-11-00887]\]. HTSeq (v0.9.0, <https://htseq.readthedocs.io>) was used to obtain the raw read counts aligned to each gene.

The TPM (transcripts per million reads) method was used to normalize the gene expression in each sample, and lowly expressed (\<5 TPM) genes were filtered. To perform differential expression analysis, we first removed individual differences among samples by filtering genes with high coefficient values (\>0.8) of standard variation in each group. An R package named as edgeR was used to calculate the statistical values for differentially expressed genes (DEGs) \[[@B30-cancers-11-00887]\] and the DEGs were identified based on the following criteria: TPM \> 5, log2 fold change (Log2FC) \> 1 or Log2FC \< −1, *p*-value \< 0.05 and FDR \< 0.05. Principle component analysis was performed using the R package "prcomp". Genome alignment files could be accessed on the National Center for Biotechnology Information (NCBI) platform under the accession number SRA893057.

2.5. Functional Analysis {#sec2dot5-cancers-11-00887}
------------------------

Functional analysis of DEGs was performed using the DAVID Bioinformatics Resources 6.8 (<https://david.ncifcrf.gov>).

2.6. Identification of SNP and Indel Variations {#sec2dot6-cancers-11-00887}
-----------------------------------------------

Variants including SNPs and indels were called using the Genome Analysis Toolkit (GATK v3.4) pipeline, according to the Best Practice workflow. In brief, the clean reads for each sample were aligned to the human reference genome (GRCH38) using the STAR 2-pass alignment steps \[[@B31-cancers-11-00887]\]. Then, the resulting SAM file was put through the usual Picard processing steps, including adding read group information, sorting, marking duplicates, and indexing (<http://broadinstitute.github.io/picard/>). Next, the RNA-Seq specific GATK tool called SplitNCigarReads was used to split the reads into exon segments and hard-clip any sequences overhanging into the intronic regions. After the indel realignment and base recalibration, we used HaplotypeCaller to call SNPs and indels, followed by variant filtering with recommended commands and parameters. We further filtered the results by removing the variants detected in less than half of the sample size. Final variants in MM patients excluded the events detected in HC. ANNOVAR was used to annotate the variants \[[@B32-cancers-11-00887]\].

2.7. Droplet Digital PCR {#sec2dot7-cancers-11-00887}
------------------------

We randomly selected 10 samples used for RNA-Seq, including three HC, two NDMM, and five RRMM patients for gene expression validation using droplet digital PCR (ddPCR). Initially, 3 mL of plasma samples were used for exRNA extraction, as described. Then, a NanoDrop 1000 was used to quantify the RNA yield. One-Step RT-ddPCR Advanced Kit for Probes (Bio-Rad Laboratories, Hercules, CA, USA) was used for the detection of five DEGs, including RGS18 (dHsaCPE5054808), ITPKA (dHsaCPE5192800), PPBP (dHsaCPE5039499), FTH1 (dHsaCPE5031151), and IER3 (dHsaCPE5190327), according to the manufacturer's instructions. Briefly, the reaction mix (22 µL) was prepared with 5 µL Supermix (1×), 2 µL reverse transcriptase (20 U/µL), 1 µL DTT (300 nM), 1 µL gene probe (900 nM), 1 µL total RNA, and 12 µL RNase-free water. Then, the droplets were generated on the Automated Droplet Generator (Bio-Rad), followed by the thermal cycling reaction. The cycling conditions were conducted on a C1000 Touch Thermal Cycler (Bio-Rad) as follows: reverse transcription (46 °C, 60 min), enzyme activation (95 °C, 10 min), 40 cycles of denaturation (95 °C, 30 s), and annealing/extension (60 °C, 1 min), and enzyme deactivation (98 °C, 10 min). After thermal cycling, the plates were read by the QX200 Droplet Reader (Bio-Rad) and the QuantaSoft software was used to analyze the data. To reduce the errors, we employed GAPDH (Glyceraldehyde-3-Phosphate Dehydrogenase) as an internal control and the gene expression was shown relative to the absolute copies of GAPDH. Aberrant values (\>500 copies/µL) were set to null, and samples with no gene expression were not counted for the calculation of the average gene expression.

3. Results {#sec3-cancers-11-00887}
==========

3.1. Characteristics of MM Patients and RNA Profiles {#sec3dot1-cancers-11-00887}
----------------------------------------------------

To investigate the biomarker potential of exRNA for NDMM and RRMM, this study recruited a total of 27 volunteers, including 10 HC (six males and four females), five NDMM (three males and two females) patients, and 12 RRMM (seven males and five females) patients. No difference was found between the groups based on gender, moreover, as shown in [Table 1](#cancers-11-00887-t001){ref-type="table"}, the mean age of NDMM (66 years) and RRMM (64.6 years) were also similar (older than the HC group: 41.9 years). After the total RNA was extracted, we evaluated the RNA profiles of exRNA using an Agilent Bioanalyzer 2100. Unlike the RNA profiles of whole cell lysates, the exRNA profiles lacked the 18S and 28S rRNA peaks ([Supplementary Figure S1](#app1-cancers-11-00887){ref-type="app"}). Whether this is one of the characteristics of exRNA requires further experiments to explore because in this instance, the exRNA sample was treated with the Ribo-Zero Gold rRNA Removal Kit.

3.2. Overview of the Transcriptome Sequencing {#sec3dot2-cancers-11-00887}
---------------------------------------------

After low-quality reads, adapter and contamination reads were filtered by SOAPnuke; we obtained a total of 762.50 million paired reads (28.24 million reads per sample on average) ([Table 2](#cancers-11-00887-t002){ref-type="table"}). The lowest Q20 and Q30 of this sequencing were 93.83% and 86.53%, respectively ([Table 2](#cancers-11-00887-t002){ref-type="table"}). Using Hisat2, 88.40--96.78% of the clean reads were aligned to the human reference genome (GRCH38), and 83.20--94.73% of the clean reads were paired matched ([Table 2](#cancers-11-00887-t002){ref-type="table"}). Then, we used Stringtie to profile the gene expression in each sample. As shown in [Table 2](#cancers-11-00887-t002){ref-type="table"}, 23,274 to 38,293 genes were identified in the MM patients and HC, respectively. We next evaluated the coverage of identified genes in each sample and found that 79.76--88.58% of the identified genes were covered more than 70% by the sequencing reads ([Figure 1](#cancers-11-00887-f001){ref-type="fig"}A). Gene annotation showed that 38.71--50.51% of the identified genes had the potential of protein-coding capacity while 1.77--2.33% of the identified genes were to be experimentally confirmed (TEC) ([Figure 1](#cancers-11-00887-f001){ref-type="fig"}B). Three long-noncoding RNAs, including RN7SL1, RN7SL2, and RN7SL4P, were the most highly expressed genes in the HC, NDMM, and RRMM samples, followed by the Metazoa_SRP (Metazoan signal recognition particle RNA).

We next analyzed the gene ontology in terms of the cellular component to source the exRNA molecules in cells. The top 20 enriched cellular components of GO were shared by NDMM, RRMM, and HC ([Figure 1](#cancers-11-00887-f001){ref-type="fig"}C). With the exception of the nucleus and the cytoplasm, the genes were enriched in the membrane and extracellular vesicle-related GO terms, such as the "plasma membrane (GO:0005886)" and "extracellular exosome (GO:0070062)".

3.3. Dysregulated exRNA in MM Patients {#sec3dot3-cancers-11-00887}
--------------------------------------

To identify potential exRNA biomarkers for NDMM and RRMM, we performed differential gene expression analysis using edgeR under the criteria described in the methods. First, we compared all the MM (NDMM + RRMM) patients to the HC and identified 375 DEGs (224 up-regulated and 151 down-regulated) ([Figure 1](#cancers-11-00887-f001){ref-type="fig"}D, [Supplementary Table S1](#app1-cancers-11-00887){ref-type="app"}). As shown in [Figure 1](#cancers-11-00887-f001){ref-type="fig"}E, 38 protein-coding genes (18 up-regulated and 20 down-regulated), 87 long noncoding genes (56 up-regulated and 31 down-regulated), 97 short noncoding genes (45 up-regulated and 52 down-regulated), and seven TEC genes (four up-regulated and three down-regulated) were differentially expressed in MM compared to HC. Apart from the immunoglobulin-related genes, GOLGA8O (golgin A8 family member O) and KCTD14 (potassium channel tetramerization domain containing 14) were the top two up-regulated genes, while the top two down-regulated genes were C21orf33 (chromosome 21 open reading frame 33) and RPL13A (ribosomal protein L13a).

Next, compared to HC, we identified 66 up-regulated and 46 down-regulated genes ([Figure 1](#cancers-11-00887-f001){ref-type="fig"}D, [Supplementary Table S1](#app1-cancers-11-00887){ref-type="app"}) in NDMM, including 13 protein-coding genes (nine up-regulated and four down-regulated), 27 long noncoding genes (16 up-regulated and 11 down-regulated), 43 pseudogenes (25 up-regulated and 18 down-regulated), 24 short noncoding genes (14 up-regulated and 10 down-regulated), and five TEC (two up-regulated and three down-regulated) ([Figure 1](#cancers-11-00887-f001){ref-type="fig"}E). The nine up-regulated protein-coding genes were MYOD1, AC009060.2, CHRNE, GOLGA8O, NKX2-4, FTH1, UBB, OLIG1, and ITPKA. The four down-regulated protein-coding genes were RGS18, HISTH1B, TRK2, and MBD3L5.

In RRMM, we identified 279 up-regulated and 200 down-regulated genes compared to HC ([Figure 1](#cancers-11-00887-f001){ref-type="fig"}D, [Supplementary Table S1](#app1-cancers-11-00887){ref-type="app"}), including 43 protein-coding genes (18 up-regulated and 25 down-regulated), 126 long noncoding genes (71 up-regulated and 55 down-regulated), 191 pseudogenes (133 up-regulated and 58 down-regulated), 111 short noncoding genes (52 up-regulated and 59 down-regulated), and eight TEC (five up-regulated and three down-regulated) ([Figure 1](#cancers-11-00887-f001){ref-type="fig"}E). The highly up-regulated protein-coding genes included immunoglobulin genes and GOLGA8O, while the highly down-regulated protein-coding genes included HIST1H4A and RPL13A.

3.4. Potential exRNA Biomarkers for MM Patients {#sec3dot4-cancers-11-00887}
-----------------------------------------------

A heat map ([Figure 2](#cancers-11-00887-f002){ref-type="fig"}A) showed that DEGs could be distinguished between MM patients and HC. This was also revealed by the principal component analysis ([Figure 2](#cancers-11-00887-f002){ref-type="fig"}B). However, due the limited sample size of the NDMM, it was difficult to separate NDMM from RRMM ([Figure 2](#cancers-11-00887-f002){ref-type="fig"}B). We next compared the DEGs identified in NDMM and RRMM. As shown in [Figure 2](#cancers-11-00887-f002){ref-type="fig"}C, 18 up-regulated and eight down-regulated genes were common to MM (NDMM + RRMM), including one up-regulated protein-coding gene (GOLGA8O) and one down-regulated protein-coding gene (TRAK2). We also identified 48 up-regulated and 38 down-regulated genes specific to NDMM ([Figure 2](#cancers-11-00887-f002){ref-type="fig"}C, [Supplementary Table S1](#app1-cancers-11-00887){ref-type="app"}), which could be utilized as potential biomarkers for NDMM. The NDMM specific up-regulated genes included seven lincRNA genes (e.g., AC007405.6, LINC00863, RP11-573G6.10, and RP11-626H12.1), one primary miRNA gene (MIR6754), and eight protein-coding genes (e.g., MYOD1, AC009060.2, CHRNE, NKX2-4, FTH1, UBB, OLIG1, and ITPKA). The NDMM specific down-regulated genes included five lincRNA genes (e.g., PACERR, LINC01123, RP11-596C23.2, and AC137934.1) and three protein-coding genes (e.g., MBD3L5, RGS18 and HIST1H1B). In addition, we identified 261 up-regulated and 192 down-regulated genes specific to RRMM ([Figure 2](#cancers-11-00887-f002){ref-type="fig"}C, [Supplementary Table S1](#app1-cancers-11-00887){ref-type="app"}). The RRMM specific dysregulated exRNA genes included 34 protein-coding genes (11 up-regulated and 23 down-regulated), 52 lincRNA genes (33 up-regulated and 19 down-regulated), 18 primary miRNA genes (10 up-regulated and eight down-regulated), and 37 misc_RNA genes (18 up-regulated and 19 down-regulated).

Next, we compared the exRNA profiles of NDMM and RRMM. Using edgeR we identified a total of 24 genes differentially expressed in RRMM relative to NDMM, including 12 up-regulated and 12 down-regulated genes ([Figure 1](#cancers-11-00887-f001){ref-type="fig"}D). The distribution of different gene types in the DEGs of RR and ND ([Figure 1](#cancers-11-00887-f001){ref-type="fig"}E) showed that six protein-coding DEGs, including two up-regulated genes (IGKV1-5 and OR4N4) and four down-regulated genes (AC017081.1, UBB, CHRNE, and USP17L17) were dysregulated in RRMM compared to NDMM. Among them, UBB and CHRNE were up-regulated in NDMM and UBB was also up-regulated in MM (NDMM + RRMM) ([Supplementary Table S1](#app1-cancers-11-00887){ref-type="app"}). Also, we found a lincRNA gene AC137934.1 up-regulated in RRMM compared to NDMM but down-regulated in NDMM compared to HC.

Functional analysis using DAVID bioinformatics resources showed that 10 and 11 DEGs in RRMM compared to HC were involved in the biological process of "SRP-dependent co-translational protein targeting to membrane" (GO:0006614) and "Ribosome" (hsa03010) pathways, respectively. Also, two DEGs in NDMM compared to HC were involved in the molecular function of "chromatin DNA binding" (GO:0031490). According to the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway annotation, we also found that ITPKA, which was up-regulated in NDMM, was related to signal transduction. Among the DEGs in the RRMM, PPBP (down-regulated) and CCL4L2 (up-regulated) were involved in the "chemokine signaling pathway" (ko04062), HIST1H4A (down-regulated) was related to "Viral carcinogenesis" (ko05203), and PCBP1 (down-regulated) was a regulator of "spliceosome" (ko03040).

3.5. Gene Variants in MM Patients {#sec3dot5-cancers-11-00887}
---------------------------------

We next used the GATK pipeline to detect SNPs and small indels in MM patients. As shown in [Figure 3](#cancers-11-00887-f003){ref-type="fig"}A, we first identified 3,606,315 SNPs in HC, of which 79,008 were found in more than five individuals. We also identified 97,547 SNPs in more than two NDMM and 159,506 SNPs in more than six RRMM. The SNPs identified in HC were classified as background and were filtered from the MM patients, resulting in 734,79 and 125,399 SNPs in NDMM and RRMM, respectively. There were 19,320 SNPs shared between NDMM and RRMM ([Figure 3](#cancers-11-00887-f003){ref-type="fig"}A). ANNOVAR was used to annotate the SNPs, and the results showed that 137 exonic SNPs were identified in both NDMM and RRMM, including one splicing event, 80 nonsynonymous, and 57 synonymous single-nucleotide variants (SNVs) ([Figure 3](#cancers-11-00887-f003){ref-type="fig"}A). The shared nonsynonymous SNPs all have been annotated in dbSNP ([Table 3](#cancers-11-00887-t003){ref-type="table"}). Seven SNPs were identified in more than four NDMM patients and more than 10 RRMM patients, including rs61821060, rs2363468, rs1941635, rs2172521, rs7199961, rs73714227, and rs4728137. rs61821060 is a mutation of the RPFIA4 gene (chr1 203039046, G-\>C) and was found in five NDMM and 11 RRMM patients. There were 388 and 861 exonic SNPs specific to NDMM and RRMM, respectively ([Figure 3](#cancers-11-00887-f003){ref-type="fig"}A). The 388 NDMM specific exonic SNPs included 168 nonsynonymous ([Supplementary Table S2](#app1-cancers-11-00887){ref-type="app"}), 219 synonymous, and one stop-loss SNP. Notably, we found one nonsynonymous SNP (chr7, 100958135, T-\>C, MUC3A) that has not been reported in the Single Nucleotide Polymorphism Database (dbSNP). The 861 RRMM specific exonic SNPs included 403 nonsynonymous ([Supplementary Table S3](#app1-cancers-11-00887){ref-type="app"}), 446 synonymous, two stop-gain and 10 unknown SNPs. Of the 403 nonsynonymous SNPs we identified five novel mutations, two occurred in MUC5AC (chr11, 1191524, T-\>C; chr11, 1191527, C-\>T), and three in MUC3A (chr7, 100953992, C-\>A; chr7, 100954123, G-\>A; chr7, 100954136, C-\>G). Next, we analyzed the mutations occurring in intestinal mucin genes, such as MUC3A, MUC5AC, MUC12 and MUC16. It was revealed that more SNPs occurred in mucin genes in RRMM than in NDMM ([Figure 3](#cancers-11-00887-f003){ref-type="fig"}B), particularly the MUC5AC gene.

We next evaluated for the presence of indels in the MM patients. As shown in [Figure 3](#cancers-11-00887-f003){ref-type="fig"}C, a total of 15,384 and 3833 indels were identified in NDMM and RRMM, respectively. NDMM and RRMM shared 1505 indels, of which one was derived from the exonic region. The shared exonic indel was annotated as rs11402251, which is located in the 10th exon of the VSIG10L gene and is a frameshift insertion. Two known indels (rs5843453 and rs55745992) were identified specifically in RRMM, while 13 known indels were identified specifically in NDMM ([Figure 3](#cancers-11-00887-f003){ref-type="fig"}D). Interestingly, nine out of the 13 NDMM specific indels had no frameshift function to their mother genes. The left indels included frameshift deletions on P2RX5 and DEFB126, frameshift insertions to GPATCH4, and a stop-gain insertion to ZNF480 ([Figure 3](#cancers-11-00887-f003){ref-type="fig"}D).

Functional analysis by DAVID showed that mutated genes for both NDMM and RRMM were involved in "Olfactory transduction (hsa04740)" and "GO:0007186\~G-protein-coupled receptor signaling pathway". In addition, RRMM specific mutated genes were also involved in "ECM-receptor interaction (hsa04512)", "GO:0007155\~cell adhesion", "GO:0071813\~lipoprotein particle binding", and "PI3K-AKT signaling pathway (hsa04151)".

3.6. Digital Droplet PCR Validation {#sec3dot6-cancers-11-00887}
-----------------------------------

We next utilized ddPCR to validate five DEGs (RGS18, ITPKA, PPBP, FTH1, and IER3) in the exRNA samples from 10 participants (three HC, two NDMM, and five RRMM). We used relative normalized expression (RNE, relative to GAPDH) to present the gene expression detected by ddPCR. [Figure 4](#cancers-11-00887-f004){ref-type="fig"} showed the comparison of gene expression identified by ddPCR and RNA-Seq. Among them, the expression levels of three genes (RGS18, ITPKA, and PPBP) were consistent between these two experiments in HC, NDMM, and RRMM. In addition, FTH1 was up-regulated in NDMM compared to HC (Log2FC = 1.78, FDR = 2.16 × 10^−7^, [Supplementary Table S1](#app1-cancers-11-00887){ref-type="app"}) and its up-regulation was also confirmed by ddPCR. The abnormal performance of FTH1 in [Figure 4](#cancers-11-00887-f004){ref-type="fig"} is due to its high expression in the three HCs. The disagreement of ddPCR and RNA-Seq on the expression change of IER3 require further experiments for validation.

4. Discussion {#sec4-cancers-11-00887}
=============

In this study, we evaluated plasma-derived exRNA from MM patients and healthy individuals ([Table 2](#cancers-11-00887-t002){ref-type="table"}). The exRNA has been reported to be subjected to degradation, instability, low abundance, and intracellular communication from specimen processing \[[@B33-cancers-11-00887],[@B34-cancers-11-00887]\]; however, in our study we demonstrated that 79.76--88.58% of the identified genes were covered more than 70%, which means that a large set of gene transcripts was complete in the exRNA tested. The stability of exRNA in the plasma or serum may be due to the protection of extracellular vesicles, such as exosomes, microparticles, microvesicles, or multivesicles \[[@B35-cancers-11-00887]\], which are shed from cellular surfaces into the bloodstream \[[@B11-cancers-11-00887]\]. In support of this, we observed that the RNA profiles generated by the Agilent Bioanalyzer 2100 were similar to exosomal RNA profiles \[[@B36-cancers-11-00887]\], which lack 18S and 28S rRNA peaks. Furthermore, our results showed that 2002--2135 genes were related to the "extracellular exosome (GO:0070062)" ([Figure 1](#cancers-11-00887-f001){ref-type="fig"}C). New evidence has shown that a large proportion of human blood plasma cf-DNA is localized in exosomes \[[@B37-cancers-11-00887]\]; however, the proportion of exosomal RNA in exRNA requires further investigation.

No studies have investigated the global transcriptome profiles of exRNA in MM. In this study, we identified genes in exRNA that could potentially be used as diagnostic and prognostic biomarkers for MM, including 18 up-regulated and eight down-regulated genes ([Figure 2](#cancers-11-00887-f002){ref-type="fig"}B, [Supplementary Table S1](#app1-cancers-11-00887){ref-type="app"}). GOLGA8O was the only up-regulated protein-coding gene common to both NDMM and RRMM. It has been reported to be significantly down-regulated in patients with major depressive disorder \[[@B38-cancers-11-00887]\]; however, the function of this gene in cancers has not been investigated. The common down-regulated genes in MM included TRAK2, a possible regulator of endosome-to-lysosome trafficking of membrane cargo, including the epidermal growth factor receptors (EGFR) \[[@B39-cancers-11-00887]\]. Endosome-to-lysosome trafficking is also an important process in exosome biogenesis \[[@B11-cancers-11-00887]\]. In addition, TRAK1, the ortholog of TRAK2, has been identified as MGb2-Ag---a novel cancer biomarker \[[@B40-cancers-11-00887]\]. In MM, the down-regulation of TRAK2 might be due to the up-regulation of miR-19a \[[@B41-cancers-11-00887],[@B42-cancers-11-00887]\], which is a member of miR-17\~92a cluster and can target the TRAK2 gene \[[@B41-cancers-11-00887]\].

In this study, we identified 54 genes specifically dysregulated in NDMM, including MYOD1, UBB, MIR6754, and PACERR ([Supplementary Table S1](#app1-cancers-11-00887){ref-type="app"}). The hypermethylation of MYOD1 has been reported to be a prognostic biomarker for both colorectal and cervical cancers \[[@B43-cancers-11-00887],[@B44-cancers-11-00887]\]. The polyubiquitin gene UBB, encoding a regulatory protein involved in ubiquitin, has been identified to be up-regulated more than 100-fold in MM patient cells versus normal twin plasma cells \[[@B45-cancers-11-00887]\]. Moreover, the knockdown of UBB can significantly decrease the expression of ubiquitin, which is essential for cancer cell growth. UBB may, therefore, represent a potential target in anticancer treatment including in MM \[[@B46-cancers-11-00887]\]. miR-6754 has been related to cell proliferation and invasion in non-small cell lung cancer \[[@B47-cancers-11-00887]\]. PACERR is the antisense gene of PGTS2 (prostaglandin-endoperoxide synthase 2) that has been related to colorectal cancer and breast cancer \[[@B48-cancers-11-00887],[@B49-cancers-11-00887]\]. There are currently no published studies that relate MIR6754 and PACERR or other noncoding RNAs to MM; however, their expression patterns in NDMM suggest that they might play a role in the progression of MM and may also represent potential biomarkers for MM.

Among the 191 genes specifically dysregulated in RRMM patients, seven down-regulated (PPBP, EEF1B2, RPL5, RPL19, CH507-9B2.3, EEF2, and RPS27) and three up-regulated (VN1R1, IER3 and POTED) protein-coding genes were identified ([Supplementary Table S1](#app1-cancers-11-00887){ref-type="app"}). Studies have reported the overexpression of most of these genes in multiple cancers, with the exception of CH507-9B2.3 \[[@B50-cancers-11-00887],[@B51-cancers-11-00887],[@B52-cancers-11-00887],[@B53-cancers-11-00887],[@B54-cancers-11-00887]\]; however, they have also been found to be down-regulated in some specific cancers. For example, the chemokine PPBP (pro-platelet basic protein), also known as CXCL7, is decreased in pancreatic and ovarian cancers \[[@B55-cancers-11-00887]\]. The eukaryotic translation elongation factors EEF1B2 and EEF2 are down-regulated in breast, esophageal, and lung cancers while EEF1B2 is found with repression in some other cancer types, such as head and neck, leukemia, and pancreatic cancer \[[@B54-cancers-11-00887]\]. Whether the down-regulation of these genes is specific to MM requires further study. Only three protein-coding genes were specifically up-regulated in RRMM, including VN1R1, POTED, and IER3 ([Supplementary Table S1](#app1-cancers-11-00887){ref-type="app"}). Among them, VN1R1 has been shown to be overexpressed in prostate adenocarcinomas and glioblastoma cancer cells \[[@B56-cancers-11-00887],[@B57-cancers-11-00887]\] and POTED in prostate cancer patients, making it a potential molecule for targeted therapy \[[@B58-cancers-11-00887]\]. Interestingly, IER3 has been shown in pancreatic ductal adenocarcinoma to effectively mitigate against cellular stress induced by starvation or exposure to gemcitabine \[[@B59-cancers-11-00887]\]. Notably, IER3 has also been demonstrated to have an anti-apoptotic role in MM endothelial cells and is overexpressed in MM plasma cells \[[@B60-cancers-11-00887]\].

In comparison to protein-coding genes, a larger proportion of noncoding DEGs were up-regulated in MM ([Supplementary Table S1](#app1-cancers-11-00887){ref-type="app"}), which is consistent with a previous study, albeit of PC-derived RNA \[[@B61-cancers-11-00887]\]. Some lncRNAs are considered to be potential promoters of MM progression, and thus, could have potential as diagnostic and prognostic biomarkers, these include LINC01215 \[[@B62-cancers-11-00887]\], MIR222HG \[[@B62-cancers-11-00887]\], MEG3 \[[@B63-cancers-11-00887]\], MALAT \[[@B64-cancers-11-00887]\], CRNDE \[[@B65-cancers-11-00887]\], and H19 \[[@B66-cancers-11-00887]\]. In this study, additional lncRNAs with biomarker potential in MM were identified ([Supplementary Table S1](#app1-cancers-11-00887){ref-type="app"}), including 65 antisense genes (e.g., FAM83C-AS1, ZNF32-AS1, TMC3-AS1, and TAT-AS1), 71 lincRNA genes (e.g., LINC00863, LINC01123, LINC00349, LINC00677, and LINC00462) and 25 primary miRNA genes (e.g., MIR301A, MIR378H, MIR425, and MIR647). Among these, some have been reported in other cancers, such as LINC01123 in prostate cancer \[[@B67-cancers-11-00887]\], LINC00677 in acute myeloid leukemia \[[@B68-cancers-11-00887]\] and LINC00462 in pancreatic cancer \[[@B69-cancers-11-00887]\]. The function of these lncRNAs in MM and their diagnostic and prognostic potential requires further evaluation.

In this study, we also identified gene variants using the transcriptome data ([Figure 3](#cancers-11-00887-f003){ref-type="fig"}). Of interest were the RRMM specific indels related to both cell adhesion and PI3K-AKT signaling pathways. Unfortunately, the hotspot mutations on KRAS, NRAS, and TP53 genes, which are common in MM \[[@B70-cancers-11-00887]\], were not identified in this study, probably due to the low coverage of these genes \[[@B71-cancers-11-00887]\]. However, our findings revealed that mucin genes, such as MUC3A, MUC5AC, MUC12, and MUC16, may play a role in MM progression, as they were frequently mutated in the MM patient, particularly the RRMM patients. Moreover, MUC16 mutations, the most frequently mutated in this analysis, have been previously demonstrated to be associated with a higher tumor mutational burden and superior survival outcomes in gastric cancer patients \[[@B72-cancers-11-00887]\]. Additionally, uterine endometrioid endometrial adenocarcinoma harbor a high-frequency of the MUC3A mutations \[[@B73-cancers-11-00887]\]. Whether mucin gene variants are derived from MM is still unknown, and our results indicate that mucin genes might be related to the MM pathogenesis. These results demonstrate the potential capacity of exRNA interrogation to identify genetic variants; however, we acknowledge that more sequencing data (high-coverage) and DNA sequencing are required to validate the genomic mutations of the described mucin genes and more patient samples are needed for large scale scanning.

5. Conclusions {#sec5-cancers-11-00887}
==============

In conclusion, this is the first transcriptome study of exRNA in cancer and in our hands, we have demonstrated that \~85% of genes in exRNA were covered more than 70% and that \~45% of exRNA genes were protein-coding genes. DEGs identified in MM patients, including GOLGA8O and TRAK2 may be potential biomarkers for the disease. Importantly, we also identified specific differentially expressed protein-coding genes in both NDMM and RRMM including cancer-associated genes such as MYOD1, UBB, VN1R1, POTED, and IER3, and while they may have potential as biomarkers also warrants further study to determine their potential role in the pathogenesis of the disease. In addition, a range of nonsynonymous mutations were identified in the exRNA, including multiple mutated mucin genes and their role in MM also warrants further evaluation. While preliminary, these data demonstrate that exRNA may represent a valuable, non-invasive compartment not only for the identification of new diagnostic and prognostic biomarkers in MM but also for the study of the biology of the disease.
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![Overview of the transcriptome of extracellular RNA (exRNA) in healthy controls (HC) and multiple myeloma (MM) patients. (**A**) Distribution of gene coverage in each sample. (**B**) Distribution of gene types in each sample. (**C**) Top 20 terms of the GO cellular component identified by the genes in HC, newly diagnosed multiple myeloma (NDMM), and relapsed and refractory multiple myeloma (RRMM). (**D**) Status of differentially expressed genes identified in MM compared to HC. (**E**) Distribution of gene types for the differentially expressed genes (DEGs).](cancers-11-00887-g001){#cancers-11-00887-f001}

![Comparison of DEGs in NDMM and RRMM. (**A**) A heat map of the DEGs showed different signatures for HC, NDMM, and RRMM. (**B**) Principle component analysis of all samples. (**C**) Venn diagrams of up- and down-regulated genes identified in all MM patients, NDMM, and RRMM.](cancers-11-00887-g002){#cancers-11-00887-f002}

![SNP and indel analysis. (**A**) Identification of SNPs in MM and their annotation. (**B**) Comparison of the distribution and the frequency of mucin gene mutations in NDMM and RRMM. (**C**) Identification of small indels in NDMM and RRMM. (**D**) Annotation of 13 known small indels specific to NDMM.](cancers-11-00887-g003){#cancers-11-00887-f003}

![Digital Droplet PCR (ddPCR) validation. Five DGEs were selected and compared to RNA-Seq. Their expression was normalized to GAPDH and was present in relative normalized expression (RNE) by ddPCR. Their normalized expression identified by RNA-Seq was shown in transcripts per million reads (TPM).](cancers-11-00887-g004){#cancers-11-00887-f004}
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###### 

Description of participants in this study. No bias was found in age or sex in the participants for each group. HC: healthy control; ND: newly diagnosed MM patient; RR: relapsed and refractory MM patient; IgA: immunoglobulin A; FISH: fluorescence in situ hybridization. Translocation t(4:14) represents the FGFR3-IGH fusion event while t(14:16) represents the IGH-MAF fusion event.

  Group             Sample   Age   Sex                   IG_Type                                    Cytogenetics
  ----------------- -------- ----- --------------------- ------------------------------------------ ---------------
  Healthy control   HC1      61    F                                                                
  HC2               36       M                                                                      
  HC3               59       M                                                                      
  HC4               65       M                                                                      
  HC5               28       F                                                                      
  HC6               64       F                                                                      
  HC7               28       M                                                                      
  HC8               28       M                                                                      
  HC9               25       F                                                                      
  HC10              25       M                                                                      
  NDMM              ND1      84    M                                                                
  ND2               75       F                                                                      
  ND3               52       M     IgA kappa             t(4;14)                                    
  ND4               54       M     IgA kappa             FISH negative for 17p, t(4;14), t(14;16)   
  ND5               65       F     IgA lambda            t(14;16)                                   
  RRMM              RR1      66    M                     IgG Lambda                                 High risk +1q
  RR2               69       F                                                                      
  RR3               62       M     IgA kappa             t(4;14) in 94% of cells on FISH            
  RR4               60       M                                                                      
  RR5               62       F                                                                      
  RR6               53       F     IgG kappa 12 g/L                                                 
  RR7               57       M                           Del 16q                                    
  RR8               64       M     IgG lambda                                                       
  RR9               71       F     Kappa Light chains                                               
  RR10              63       M     IgG lambda                                                       
  RR11              77       F     IgG kappa                                                        
  RR12              71       M     Lambda light chains                                              

NDMM---newly diagnosed multiple myeloma; RRMM---relapsed and refractory multiple myeloma.
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###### 

Overview of the extracellular RNA (exRNA) transcriptome sequencing. Q20 and Q30 were applied to the clean reads. The number of mapped reads was given by Hisat2 and '.5' means that one of the paired reads was mapped. Percentages were calculated for mapped reads and paired reads matched to the genome. The numbers of genes identified in the samples (\>5 transcripts per million reads (TPM)) were listed.

  Sample   Clean Reads ^a^   Q20 (%)   Q30 (%)   Mapped Reads ^b^   Percentage (%)   Paired Mapping   Percentage (%)   Genes
  -------- ----------------- --------- --------- ------------------ ---------------- ---------------- ---------------- -------
  HC1      35514538          94.33     87.06     32335527           91.05            30805744         86.74            25298
  HC2      32851123          94.46     87.49     29510065.5         89.83            28039748         85.35            26253
  HC3      35037913          94.62     87.77     31689161           90.44            30111659         85.94            26193
  HC4      20540654          95.99     93.73     19878330           96.78            19459041         94.73            32587
  HC5      20440423          96.36     94.31     19465740           95.23            19125751         93.57            37620
  HC6      21051811          96.36     94.33     20066691           95.32            19697560         93.57            36927
  HC7      20663077          96.44     94.44     19753850           95.60            19378872         93.79            37271
  HC8      21280234          96.38     94.34     20188191.5         94.87            19770401         92.90            37180
  HC9      20233979          96.37     94.33     19270979.5         95.24            18855816         93.19            37431
  HC10     25312716          95.33     88.25     24087393.5         95.16            23479329         92.76            34429
  ND1      28398995          95.66     89.04     26841732.5         94.52            26201952         92.26            35206
  ND2      30255712          94.45     86.67     28480977           94.13            27722552         91.63            28239
  ND3      30676993          95.38     88.42     28961701           94.41            28258901         92.12            33733
  ND4      32996329          95.44     88.45     31421035.5         95.23            30717044         93.09            33671
  ND5      29687796          95.15     88.03     27781572.5         93.58            27023016         91.02            34465
  RR1      23654835          96.18     94.07     22562264           95.38            22117174         93.50            38293
  RR2      34826086          95.48     89.72     31683769.5         90.98            29855275         85.73            24750
  RR3      34519866          95.27     89.64     31195727           90.37            29771168         86.24            27030
  RR4      19760808          96.19     94.09     18778665.5         95.03            18400771         93.12            36728
  RR5      37935946          93.83     86.53     33533599           88.40            31563842         83.20            23274
  RR6      21276042          95.97     93.69     20306633.5         95.44            19920078         93.63            37483
  RR7      35570784          94.94     89.04     31696004           89.11            30025680         84.41            27430
  RR8      21689934          96.37     94.35     20580676.5         94.89            20153418         92.92            37363
  RR9      35093968          95.31     89.64     31801951           90.62            30321993         86.40            26195
  RR10     36654365          94.14     87.09     33462054           91.29            31837012         86.86            23714
  RR11     21643768          96.26     94.21     20526202           94.84            20149268         93.10            37348
  RR12     34935598          95.30     89.67     31878267           91.25            30410198         87.05            25557
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###### 

Common nonsynonymous SNPs identified in NDMM and RRMM. The number of NDMM and RRMM patients were listed.

  dbSNP          Chromosome   Locus       Ref   Alt   Gene        NDMM   RRMM
  -------------- ------------ ----------- ----- ----- ----------- ------ ------
  rs61821060     chr1         203039046   G     C     PPFIA4      5      11
  rs2363468      chr2         208325606   T     C     PIKFYVE     4      11
  rs1941635      chr11        118111780   T     G     TMPRSS4     4      10
  rs2172521      chr12        57810500    T     C     AVIL        4      10
  rs7199961      chr16        88428999    G     C     ZNF469      4      10
  rs73714227     chr7         100952147   C     T     MUC3A       4      10
  rs4728137      chr7         128815713   C     G     CCDC136     4      10
  rs870124       chr1         3411794     T     C     PRDM16      4      9
  rs4951168      chr1         205084091   C     T     TMEM81      4      9
  rs6491707      chr13        102732665   A     G     CCDC168     4      9
  rs35708006     chr15        23441451    T     C     GOLGA6L2    4      9
  rs7197779      chr16        10909070    A     G     CIITA       4      9
  rs673918       chr17        77194764    A     C     SEC14L1     4      9
  rs3746887      chr21        39660813    T     C     B3GALT5     4      9
  rs130642       chr22        46281710    T     C     TTC38       4      9
  rs9831516      chr3         69180910    G     A     FRMD4B      4      9
  rs2261167      chr4         40808730    A     G     NSUN7       4      9
  rs4728329      chr7         134541075   A     G     AKR1B10     5      9
  rs615474       chr9         35043294    G     T     C9orf131    4      9
  rs2215530      chr9         122724689   G     A     OR1L4       4      9
  rs3748597      chr1         953279      T     C     NOC2L       4      8
  rs10776792     chr1         115033402   A     G     TSHB        4      8
  rs1144566      chr1         182600491   T     C     RGS16       4      8
  rs28533004     chr1         248650751   T     A     OR2T27      5      8
  rs2653588      chr11        8925474     A     G     C11orf16    5      8
  rs540687       chr11        57379543    A     G     PRG3        5      8
  rs1194099      chr11        65582378    A     T     EHBP1L1     4      8
  rs929949       chr12        27696863    A     G     REP15       4      8
  rs59122400     chr15        23441526    G     A     GOLGA6L2    5      8
  rs8026845      chr15        44674191    T     C     PATL2       4      8
  rs8071623      chr17        58543925    G     T     C17orf47    4      8
  rs8104843      chr19        15087481    C     G     OR1I1       4      8
  rs4806163      chr19        35513204    A     G     DMKN        5      8
  rs1059768      chr20        56513348    A     G     RTFDC1      5      8
  rs2931761      chr3         112471290   G     T     BTLA        5      8
  rs6831040      chr4         81046034    C     T     BMP3        4      8
  rs699512       chr7         43771165    G     A     BLVRA       4      8
  rs1043708507   chr7         100955225   T     A     MUC3A       4      8
  rs3118635      chr9         129098622   G     T     CRAT        4      8
  rs10864628     chr1         6575171     A     G     TAS1R1      4      7
  rs198400       chr1         11824498    A     G     CLCN6       4      7
  rs10480        chr1         150308112   T     C     MRPS21      4      7
  rs863363       chr1         158579721   A     G     OR10X1      4      7
  rs859398       chr1         175406666   T     C     TNR         4      7
  rs2243525      chr1         236543562   G     C     LGALS8      4      7
  rs10736251     chr10        116471848   G     A     PNLIPRP3    4      7
  rs1897519      chr10        116471851   A     G     PNLIPRP3    4      7
  rs7088479      chr10        123746786   T     C     CPXM2       4      7
  rs2255246      chr10        133420037   A     G     MTG1        5      7
  rs564271       chr11        1835943     T     C     SYT8        4      7
  rs10768611     chr11        5151556     A     G     OR52A1      4      7
  rs2682123      chr11        6320454     C     G     CAVIN3      4      7
  rs2958149      chr12        56716008    A     G     NACA        4      7
  rs9300758      chr13        102735870   A     G     CCDC168     4      7
  rs9514066      chr13        102875499   G     C     ERCC5       4      7
  rs12896533     chr14        19748139    T     C     OR4Q3       4      7
  rs1280395      chr15        57439137    A     C     CGNL1       5      7
  rs7168069      chr15        68332058    A     C     ITGA11      4      7
  rs4787984      chr16        27761580    G     A     KIAA0556    4      7
  rs9932770      chr16        29697029    A     G     QPRT        5      7
  rs235638       chr16        29780400    G     C     ZG16        4      7
  rs4782300      chr16        88431813    C     T     ZNF469      4      7
  rs897420       chr17        41514660    G     C     KRT15       4      7
  rs2429387      chr17        62689654    G     A     MRC2        4      7
  rs1688149      chr17        74866908    C     T     FDXR        4      7
  rs820256       chr17        75594749    T     G     MYO15B      4      7
  rs2287803      chr19        10001670    T     C     COL5A3      5      7
  rs2285422      chr19        36006456    C     G     SYNE4       4      7
  rs3103057      chr19        56053798    G     A     NLRP5       4      7
  rs2444257      chr2         151465581   A     T     RIF1        4      7
  rs6436669      chr2         227248459   A     G     COL4A3      4      7
  rs1033545      chr20        18315428    T     A     ZNF133      5      7
  rs6076122      chr20        23750857    A     G     CST1        4      7
  rs910148       chr20        62881254    T     C     DIDO1       4      7
  rs464391       chr21        44579776    G     C     KRTAP10-5   5      7
  rs6787916      chr3         52833699    G     C     MUSTN1      4      7
  rs28376231     chr5         177503134   G     A     DOK3        4      7
  rs28463186     chr7         100995575   A     G     MUC12       4      7
  rs6558339      chr8         143249842   T     C     ZFP41       4      7
  rs62547039     chr9         34725745    T     C     FAM205A     4      7

[^1]: These authors contribute equally to the work.
